Compare ASML & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASML | AZN |
|---|---|---|
| Founded | 1984 | 1992 |
| Country | Netherlands | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.6B | 285.7B |
| IPO Year | N/A | N/A |
| Metric | ASML | AZN |
|---|---|---|
| Price | $1,363.75 | $200.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $1,475.86 | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 2.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 0.46% | ★ 1.57% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.35 | $9.84 |
| Revenue Next Year | $18.04 | $6.16 |
| P/E Ratio | $50.62 | ★ $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $578.51 | $61.24 |
| 52 Week High | $1,547.22 | $212.71 |
| Indicator | ASML | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 44.22 | 69.19 |
| Support Level | $1,316.06 | $89.28 |
| Resistance Level | $1,493.99 | $212.71 |
| Average True Range (ATR) | 40.32 | 3.36 |
| MACD | -14.92 | -3.76 |
| Stochastic Oscillator | 16.84 | 21.20 |
ASML is the market leader in lithography systems for manufacturing semiconductors. Lithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. Lithography allows chipmakers to increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML's largest clients are TSMC, Samsung, and Intel.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.